Publications

You may also search for publications by trial by visiting our trial index.

For information on the entire TIMI Study Group publication library, contact our Academic Coordinator

Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. van Diepen S, Tymchak W, Bohua EA, Park J-G, Daniels LB, Phreaner N, Barnett CF, Kenigsberg BB, De Filippis A, Singam NS, Barsness GW, Jentzer JC, Ternus B, Morrow DA, Katz JN, Critical Care Cardiology Trials Network Investigators. Am Heart J. 2020 Apr;222:8-14. doi: 10.1016/j.ahj.2020.01.005.

Advanced Respiratory Support in the Contemporary Cardiac ICU. Metkus TS, Miller PE, Alviar CL, Baird-Zars VM, Bohula EA, Cremer PC, Gerber DA, Jentzer JC, Keeley EC, Kontos MC, Menon V, Park J-G, Roswell RO, Schulman SP, Solomon MA, van Diepen S, Katz JN, Morrow DA. Critical Care Explorations: September 2020 – Volume 2 – Issue 9 – p. e0182.

Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. Xu H, Yang Y, Wang C, Yang J, Li W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan X, Gao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SD; China Acute Myocardial Infarction Registry Investigators. JAMA Netw Open. 2020 Oct 1;3(10):e2021677. doi: 10.1001/jamanetworkopen.2020.21677.

Practice pattern of use of high sensitivity troponin in the outpatient settings. Ferro EG, Bhatt AS, Zhou G, Fiumara K, Wasfy JH, Sequist TD, Morrow DA, Scirica BM. Clin Cardiol. 2020 Oct 22. doi: 10.1002/clc.23482.

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees.
Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402.

Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV Jr, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG; TAO investigators. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20:2048872619896205. doi: 10.1177/2048872619896205.

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkely B, O’Meara E, Schou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV. Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.

Left Ventricular Unloading is Associated with Lower Mortality in Cardiogenic Shock Patients Treated with Veno-Arterial Extracorporeal Membrane Oxygenation: Results From An International, Multicenter Cohort Study. Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, Colson P, Cudemus Deseda G, Dabboura S, Eckner D, Eden M, Eitel I, Frank D, Frey N, Funamoto M, Goßling A, Graf T, Hagl C, Kirchhof P, Kupka D, Landmesser U, Lipinski J, Lopes M, Majunke N, Maniuc O, McGrath D, Möbius-Winkler S, Morrow DA, Mourad M, Noel C, Nordbeck P, Orban M, Pappalardo F, Patel SM, Pauschinger M, Pazzanese V, Reichenspurner H, Sandri M, Schulze PC, Schwinger RHG, Sinning JM, Aksoy A, Skurk C, Szczanowicz L, Thiele H, Tietz F, Varshney A, Wechsler L, Westermann D. Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.048792.

Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. Samsky MD, Krucoff MW, Morrow DA, Abraham WT, Aguel F, Althouse AD, Chen E, Cigarroa JE, DeVore AD, Farb A, Gilchrist IC, Henry TD, Hochman JH, Kapur NK, Morrow V, Ohman EM, O’Neill WW, Piña IL, Proudfoot AG, Sapirstein JS, Seltzer JH, Senatore F, Shinnar M, Simonton CA, Tehrani BN, Thiele H, Truesdell AG, Waksman R, Rao SV. Am Heart J. 2020 Oct 1:S0002-8703(20)30271-4. doi: 10.1016/j.ahj.2020.09.015.

Reply to: COVID-19 Related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. Menon AA, Berg DD, Gay EB, Fredenburgh LE; all the authors of “A Case of COVID-19 and Pneumocystis jirovecii Co-infection”. Am J Respir Crit Care Med. 2020 Sep 17. doi: 10.1164/rccm.202008-3174LE.

Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. Desai AS, Maclean T, Blood AJ, Bosque-Hamilton J, Dunning J, Fischer C, Fera L, Smith KV, Wagholikar K, Zelle D, Gaziano T, Plutzky J, Scirica B, MacRae CA. JAMA Cardiol. 2020 Sep 16. doi: 10.1001/jamacardio.2020.3757.

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP. Thromb Haemost. 2020 Sep 13. doi: 10.1055/s-0040-1716540.

Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O’Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD; PIONEER-HF Investigators. JACC Heart Fail. 2020 Sep 4:S2213-1779(20)30452-2. doi: 10.1016/j.jchf.2020.06.019.

Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”. Zelniker TA, Raz I, Sabatine MS, Wiviott SD. Circulation. 2020 Sep 8;142(10):e129-e130. doi: 10.1161/CIRCULATIONAHA.120.049841. Epub 2020 Sep 8. 

Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau JC, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.120.047480.

Invasive or Conservative Strategy for Stable Coronary Disease. Reply. Antman EM, Braunwald E. N Engl J Med. 2020 Sep 3;383(10):e66. doi: 10.1056/NEJMc2024008.

Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. Jentzer JC, Bihorac A, Brusca SB, Del Rio-Pertuz G, Kashani K, Kazory A, Kellum JA, Mao M, Moriyama B, Morrow DA, Patel HN, Rali AS, van Diepen S, Solomon MA; Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council. J Am Coll Cardiol. 2020 Sep 1;76(9):1084-1101. doi: 10.1016/j.jacc.2020.06.070.

Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ; PIONEER-HF Investigators. J Am Coll Cardiol. 2020 Sep 1;76(9):1034-1048.

Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents -Post-hoc Analyses from DECLARE-TIMI 58. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I. Diabetes Obes Metab. 2020 Aug 26. doi: 10.1111/dom.14179.

Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. McCarthy CP, Murphy S, Jones-O’Connor M, Olshan DS, Khambhati JR, Rehman S, Cadigan JB, Cui J, Meyerowitz EA, Philippides G, Friedman LS, Kadar AY, Hibbert K, Natarajan P, Massaro AF, Bohula EA, Morrow DA, Woolley AE, Januzzi JL Jr, Wasfy JH. EClinicalMedicine. 2020 Aug 19:100504. doi: 10.1016/j.eclinm.2020.100504.

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV. Eur Heart J. 2020 Aug 21:ehaa496. doi: 10.1093/eurheartj/ehaa496.

Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA. JACC Heart Fail. 2020 Aug 7:S2213-1779(20)30384-X. doi: 10.1016/j.jchf.2020.06.008.

Dapagliflozin and Cardiac, Kidney and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, Furtado RHM, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Circulation. 2020 Aug 3. doi: 10.1161/CIRCULATIONAHA.119.044775.

Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay’s Limit of Detection? Wu AHB, Kavsak PA, Aakre KM, Christenson RH, Apple FS, Peacock WF, Hollander JE, de Lemos JA, Morrow D, Januzzi J, Jaffe AS. Clin Chem. 2020 Aug 12:hvaa160. doi: 10.1093/clinchem/hvaa160.

Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. JAMA Cardiol. 2020 Aug 12. doi: 10.1001/jamacardio.2020.2822.

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. JAMA Cardiol. 2020 Aug 12. doi: 10.1001/jamacardio.2020.3151.

Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. JAMA Cardiol. 2020 Aug 5. doi: 10.1001/jamacardio.2020.2981.

Pooling Data From Individual Clinical Trials in the COVID-19 Era. Petkova E, Antman EM, Troxel AB. JAMA. 2020 Jul 22. doi: 10.1001/jama.2020.13042.

Multimodality Imaging in Evaluation of Cardiovascular complications in Patients with COVID-19. Rudski L, Januzzi JL, Rigolin VH, Bohula EA, Blankstein R, Patel AR, Bucciarelli-Ducci C, Vorovich E, Mukherjee M, Rao SV, Beanlands R, Villines TC, Di Carli MF. J Am Coll Cardiol. 2020 Jul 20:S0735-1097(20)36039-3. doi: 10.1016/j.jacc.2020.06.080.

Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.  Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O’Donoghue ML.  J Thromb Thrombolysis. 2020 Jul 18. doi: 10.1007/s11239-020-02221-5.

Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF.  Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, Demets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Circulation. 2020 Jul 16. doi: 10.1161/CIRCULATIONAHA.120.047077.

Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?  Bergmark BA.  J Am Heart Assoc. 2020 Jul 14:e017888. doi: 10.1161/JAHA.120.017888.

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Solomon SD, Jhund PS, Claggett BL, Dewan P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJV. JACC Heart Fail. 2020 Jul 5. pii: S2213-1779(20)30254-7.

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. JACC Heart Fail. 2020 Jun 10. pii: S2213-1779(20)30272-9. doi: 10.1016/j.jchf.2020.05.005.

Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Gencer B, Giugliano RP. Clin Cardiol. 2020 Jun 29. doi: 10.1002/clc.23410.

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack CV, Wiviott SD, Rao SV, Jukema JW, Erglis A, Moccetti T, Elbez Y, Steg PG. Int J Cardiol. 2020 Jun 23. pii: S0167-5273(20)33398-2.

The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. O’Donoghue ML, Murphy SA, Sabatine MS. Circulation. 2020 Jun 19. doi: 10.1161/CIRCULATIONAHA.120.046251.

The American Heart Association COVID-19 CVD Registry powered by Get With The Guidelines®. Alger HM, Rutan C, Williams Iv JH, Walchok JG, Bolles M, Hall JL, Bradley SM, Elkind MSV, Rodriguez F, Wang TY, Morrow DA, Das SR, de Lemos JA. Circ Cardiovasc Qual Outcomes. 2020 Jun 17. doi: 10.1161/CIRCOUTCOMES.120.006967.

Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Bělohlávek J, Chopra VK, Dukát A, Kitakaze M, Merkely B, O’Meara E, Schou M, Vinh PN, McMurray JJV; DAPA-HF Investigators and Committees. Eur J Heart Fail. 2020 Jun 15. doi: 10.1002/ejhf.1867.

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. Dietz N, Ruff C, Giugliano RP, Mercuri MF, Antman EM. Int J Cardiol. 2020 Mar 21. pii: S0167-5273(19)33781-7. doi: 10.1016/j.ijcard.2020.03.055.

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, Ezekowitz J, Filippatos G, Friede T, Hernandez AF, Lam CSP, Lindenfeld J, McMurray JJV, Mehra M, Metra M, Packer M, Pieske B, Pocock SJ, Ponikowski P, Rosano GMC, Teerlink JR, Tsutsui H, Van Veldhuisen DJ, Verma S, Voors AA, Wittes J, Zannad F, Zhang J, Seferovic P, Coats AJS. Eur Heart J. 2020 Jun 4. pii: ehaa461. doi: 10.1093/eurheartj/ehaa461.

A current review of COVID-19 for the cardiovascular specialist. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. Am Heart J. 2020 May 3;226:29-44. doi: 10.1016/j.ahj.2020.04.025.

Left ventricle unloading strategies in ECMO: A single-center experience. Piechura LM, Coppolino A, Mody GN, Rinewalt DE, Keshk M, Ogawa M, Seethala R, Bohula EA, Morrow DA, Singh SK, Mallidi HR, Keller SP. J Card Surg. 2020 Jun 2. doi: 10.1111/jocs.14644.

Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Napp LC, Cammann VL, Jaguszewski M, Szawan KA, Wischnewsky M, Gili S, Knorr M, Heiner S, Citro R, Bossone E, D’Ascenzo F, Neuhaus M, Franke J, Sorici-Barb I, Noutsias M, Burgdorf C, Koenig W, Kherad B, Sarcon A, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Pott A, Meyer P, Arroja JD, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Hauck C, Paolini C, Bilato C, Imori Y, Kato K, Kobayashi Y, Opolski G, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Dichtl W, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Horowitz JD, Polednikova K, Tousek P, Widimský P, Winchester DE, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Di Mario C, Prasad A, Rihal CS, Schulze PC, Bianco M, Crea F, Borggrefe M, Maier LS, Pinto FJ, Braun-Dullaeus RC, Rottbauer W, Katus HA, Hasenfuß G, Tschöpe C, Pieske BM, Thiele H, Schunkert H, Böhm M, Felix SB, Münzel T, Bax JJ, Bauersachs J, Braunwald E, Lüscher TF, Ruschitzka F, Ghadri JR, Templin C. Eur Heart J. 2020 Jun 2. pii: ehaa210. doi: 10.1093/eurheartj/ehaa210.

MRI-EEG correlation for outcome prediction in postanoxic myoclonus: A multicenter study. Beuchat I, Sivaraju A, Amorim E, Gilmore EJ, Dunet V, Rossetti AO, Westover MB, Hsu L, Scirica BM, Silva D, Tang K, Lee JW. Neurology. 2020 Jun 1. pii: 10.1212/WNL.0000000000009610. doi: 10.1212/WNL.0000000000009610.

Reversal Agents: What We Have and What We Can Expect. Ruff CT. J Innov Card Rhythm Manag. 2018 Apr 15;9(4):3108-3114. doi: 10.19102/icrm.2018.090403. eCollection 2018 Apr. Review.

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. JAMA Cardiol. 2020 May 20. doi: 10.1001/jamacardio.2020.0882.

Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. Wang SY, Giugliano RP. Am J Cardiol. 2020 Apr 23. pii: S0002-9149(20)30384-2. doi: 10.1016/j.amjcard.2020.04.016. [Epub ahead of print] Review.

HRS white paper on atrial fibrillation centers of excellence: Rationale, considerations, and goals. Piccini JP Sr, Allred J, Bunch TJ, Deering TF, Di Biase L, Hussein AA, Lewis WR, Mittal S, Natale A, Osorio J, Packer DL, Ruff C, Russo AM, Sanders P, Seiler A, Slotwiner D, Hills MT, Turakhia MP, Van Gelder IC, Varosy PD, Verma A, Volgman AS, Wood KA, Deneke T. Heart Rhythm. 2020 May 3. pii: S1547-5271(20)30407-0. doi: 10.1016/j.hrthm.2020.04.033.

Cognition After Lowering LDL-Cholesterol With Evolocumab. Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pedersen TR, Keech AC, Ott BR, Sabatine MS, Giugliano RP; FOURIER Investigators. J Am Coll Cardiol. 2020 May 12;75(18):2283-2293. doi: 10.1016/j.jacc.2020.03.039.

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. J Am Heart Assoc. 2020 May 5:e015331. doi: 10.1161/JAHA.119.015331.

Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. Barkoudah E, Piazza G, Hecht TEH, Grant P, Deitelzweig S, Fang MC, Fanikos J, Kao CK, Barnes GD, Chen T, Ramishvili T, Schnipper JL, Goldstein JN, Ruff CT, Kaatz S, Schwartz A, Connors JM, Goldhaber SZ. Am J Med. 2020 May;133 Suppl 1:1-27. doi: 10.1016/j.amjmed.2019.12.001.

Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS. JAMA Cardiol. 2020 Apr 29. doi: 10.1001/jamacardio.2020.0764.

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. Bergmark BA, O’Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceška R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS. JAMA Cardiol. 2020 Apr 29. doi: 10.1001/jamacardio.2020.0728.

No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.  Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin L.  JACC Cardiovasc Interv. 2020 Apr 27;13(8):1012-1014. doi: 10.1016/j.jcin.2020.02.009.

Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction.  Metkus T, Miller PE, Alviar CL, Jentzer JC, van Diepen S, Katz JN, Morrow DA, Schulman S, Eid S.  Eur Heart J Acute Cardiovasc Care. 2020 Apr 23:2048872620919947. doi: 10.1177/2048872620919947.

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.  Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, Murphy SA, Wasserman SM, Honarpour N, Wang H, Lira Pineda A, Sabatine MS; FOURIER Investigators.  Stroke. 2020 Apr 21:STROKEAHA119027759. doi: 10.1161/STROKEAHA.119.027759.

Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population. Jentzer JC, van Diepen S, Murphree DH, Ismail AS, Keegan MT, Morrow DA, Barsness GW, Anavekar NS. Am Heart J. 2020 Feb 28;224:57-64. doi: 10.1016/j.ahj.2020.02.018.

Disruptive Modifications to Cardiac Critical Care Delivery During the Covid-19 Pandemic: An International Perspective. Katz JN, Sinha SS, Alviar CL, Dudzinski DM, Gage A, Brusca SB, Flanagan MC, Welch T, Geller BJ, Miller PE, Leonardi S, Bohula EA, Price S, Chaudhry SP, Metkus TS, O’Brien CG, Sionis A, Barnett CF, Jentzer JC, Solomon MA, Morrow DA, van Diepen S. J Am Coll Cardiol. 2020 Apr 14. pii: S0735-1097(20)35002-6. doi: 10.1016/j.jacc.2020.04.029.

Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. Varshney AS, Berg DD, Katz JN, Baird-Zars VM, Bohula EA, Carnicelli AP, Chaudhry SP, Guo J, Lawler PR, Nativi-Nicolau J, Sinha SS, Teuteberg JJ, van Diepen S, Morrow DA; Critical Care Cardiology Trials Network Investigators. JAMA Cardiol. 2020 Apr 15. doi: 10.1001/jamacardio.2020.0692.

COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies. Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. JACC Basic Transl Sci. 2020 Apr 10. doi: 10.1016/j.jacbts.2020.04.002.

Understanding the Sex Paradox After Percutaneous Coronary Intervention: Leveling the Playing Field. O’Donoghue ML, Sarma AA. J Am Coll Cardiol. 2020 Apr 14;75(14):1641-1643. doi: 10.1016/j.jacc.2020.02.048.

The Promise of Mobile Health in Managing Atrial Fibrillation. Ruff CT. J Am Coll Cardiol. 2020 Apr 7;75(13):1535-1537. doi: 10.1016/j.jacc.2020.02.039.

Safety of dapagliflozin in a broad population of patients with type 2 diabetes – analyses from the DECLARE – TIMI 58 study. Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Diabetes Obes Metab. 2020 Apr 2. doi: 10.1111/dom.14041.

Managing Stable Ischemic Heart Disease. Antman EM, Braunwald E. N Engl J Med. 2020 Mar 30. doi: 10.1056/NEJMe2000239. PMID: 32227752

The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O’Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS. Circulation. 2020 Mar 29. doi: 10.1161/CIRCULATIONAHA.120.046397.

Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Vaduganathan M, Singh A, Sharma A, Januzzi JL Jr, Scirica BM, Butler J, Zannad F, McGuire DK, Cannon CP, Bhatt DL. Am J Cardiol. 2020 Mar 4. pii: S0002-9149(20)30175-2. doi: 10.1016/j.amjcard.2020.01.053.

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, Katova T, Ljungman CEA, O’Meara E, Petrie MC, Schou M, Verma S, Vinh PN, Solomon SD, McMurray JJV. Eur Heart J. 2020 Mar 28. pii: ehaa183. doi: 10.1093/eurheartj/ehaa183.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.1906.

Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. J Am Coll Cardiol. 2020 Mar 17;75(10):1095-1106. doi: 10.1016/j.jacc.2019.12.067.

Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. Menown IBA, Giugliano R, Zeymer U. Cardiol Ther. 2020 Mar 6. doi: 10.1007/s40119-020-00166-7.

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial.
Bajaj HS, Raz I, Mosenzon O, Murphy SA, Rozenberg A, Yanuv I, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Sabatine MS, Wiviott SD, Cahn A. Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011.

Percutaneous right ventricular assist device-supported ventricular tachycardia ablation in a patient with severe right ventricular dysfunction. Aguilar M, Tsao AL, Croce KJ, Sauer W, Morrow DA, Tedrow UB. HeartRhythm Case Rep. 2019 Nov 4;6(2):72-76. doi: 10.1016/j.hrcr.2019.10.019. eCollection 2020 Feb.

Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. Bandyopadhyay D, Chakraborty S, Amgai B, Kapadia SR, Braunwald E, Naidu SS, Kalra A.JAMA Netw Open. 2020 Feb 5;3(2):e1921669. doi: 10.1001/jamanetworkopen.2019.21669.

2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee. Writing Committee Members, Yancy CW, Drazner MH, Coffin ST, Cornwell W 3rd, Desai S, Erwin JP 3rd, Ginwalla M, Harshaw-Ellis KS, Horwich T, Kittleson M, Lala A, Lewsey SC, Marine JE, Martin CM, Meehan K, Morrow DA, Schlendorf K, Smith JW, Stevens GR. J Am Coll Cardiol. 2020 Feb 14. pii: S0735-1097(19)37741-1. doi: 10.1016/j.jacc.2019.09.030.

Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. Sun MT, Huang S, Wiviott SD, Antman EM, Roe MT, Ohman EM, Neely M, Wallentin L, Wong CX. Am J Cardiol. 2020 Jan 29. pii: S0002-9149(20)30053-9. doi: 10.1016/j.amjcard.2020.01.012.

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Nanna MG, Navar AM, Giugliano RP, White JA, Lokhnygina Y, Mitchel YB, Musliner TA, Cannon CP, Blazing MA. J Am Coll Cardiol. 2020 Feb 25;75(7):835-837. doi: 10.1016/j.jacc.2019.12.022.

Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel? Furtado RHM, Bergmark B. Eur J Heart Fail. 2020 Feb 11. doi: 10.1002/ejhf.1717.

Positive Pressure Ventilation in Cardiogenic Shock: Review of the Evidence and Practical Advice for Patients With Mechanical Circulatory Support. Alviar CL, Rico-Mesa JS, Morrow DA, Thiele H, Miller PE, Maselli DJ, van Diepen S. Can J Cardiol. 2020 Feb;36(2):300-312. doi: 10.1016/j.cjca.2019.11.038. Epub 2019 Dec 12. Review.

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Plitt A, Ruff CT, Goudev A, Morais J, Ostojic MC, Grosso MA, Lanz HJ, Park JG, Antman EM, Braunwald E, Giugliano RP. Int J Cardiol. 2020 Jan 30. pii: S0167-5273(19)35229-5. doi: 10.1016/j.ijcard.2020.01.009.

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O’Donoghue ML. Eur J Prev Cardiol. 2020 Feb 4:2047487320902750. doi: 10.1177/2047487320902750.

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Furtado RHM, Giugliano RP. Cardiol Ther. 2020 Feb 5. doi: 10.1007/s40119-020-00163-w. Review.

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Zelniker TA, Braunwald E. J Am Coll Cardiol. 2020 Feb 4;75(4):435-447. doi: 10.1016/j.jacc.2019.11.036. Review.

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Zelniker TA, Braunwald E. J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031. Review.

Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Vasc Med. 2020 Jan 30:1358863X19892690. doi: 10.1177/1358863X19892690.

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott SD, McMurray JJV, Granger CB. Circulation. 2020 Jan 29. doi: 10.1161/CIRCULATIONAHA.119.041022.

Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”.  Bergmark BA, Bhatt DL, McGuire DK, Scirica BM. Circulation. 2020 Jan 28;141(4):e57-e58. doi: 10.1161/CIRCULATIONAHA.119.044819. Epub 2020 Jan 27.

Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial. Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183.

Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. van Diepen S, Tymchak W, Bohula EA, Park JG, Daniels LB, Phreaner N, Barnett CF, Kenigsberg BB, DeFilippis A, Singam NS, Barsness GW, Jentzer JC, Ternus B, Morrow DA, Katz JN; Critical Care Cardiology Trials Network Investigators. Am Heart J. 2020 Jan 15;222:8-14. doi: 10.1016/j.ahj.2020.01.005.

The Fourth Universal Definition of Myocardial Infarction and the Emerging Importance of Myocardial Injury. Morrow DA. Circulation. 2020 Jan 21;141(3):172-175. doi: 10.1161/CIRCULATIONAHA.119.044125. Epub 2020 Jan 20.

American Heart Association Vascular Disease Strategically Focused Research Network. Barnett JV1, Beckman JA, Bonaca MP, Carnethon MR, Cassis LA, Creager MA, Daugherty A, Feinberg MW, Freiberg MS, Goodney PP, Greenland P, Leeuwenburgh C, LeMaire SA, McDermott MM, Sabatine MS, Shen YH, Wasserman DH, Webb NR, Wells QS. Arterioscler Thromb Vasc Biol. 2020 Jan 23:ATVBAHA120313967. doi: 10.1161/ATVBAHA.120.313967.

Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. J Am Coll Cardiol. 2020 Jan 28;75(3):289-300. doi: 10.1016/j.jacc.2019.11.035.

Atrial Failure as a Clinical Entity: JACC Review Topic of the Week. Bisbal F, Baranchuk A, Braunwald E, Bayés de Luna A, Bayés-Genís A. J Am Coll Cardiol. 2020 Jan 21;75(2):222-232. doi: 10.1016/j.jacc.2019.11.013. Review.

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Shah S et al. Nat Commun. 2020 Jan 9;11(1):163. doi: 10.1038/s41467-019-13690-5.

Notable TIMI publications from 2019:Graph

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). Alkhalfan F, Nafee T, Yee MK, Chi G, Kalayci A, Plotnikov A, Braunwald E, Gibson CM. Am J Cardiol. 2019 Dec 9. pii: S0002-9149(19)31363-3. doi: 10.1016/j.amjcard.2019.12.007.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O’Donoghue ML. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022. doi: 10.1016/j.jacc.2019.09.065. Epub 2019 Dec 9.

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Diabetes Care. 2019 Dec 16. pii: dc191476. doi: 10.2337/dc19-1476.

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O’Connor CM. Circulation. 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16.

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ; PIONEER-HF Investigators.  JAMA Cardiol. 2019 Dec 11. doi: 10.1001/jamacardio.2019.4665.

Respiratory support in acute heart failure with preserved vs reduced ejection fraction. Metkus TS, Stephens RS, Schulman S, Hsu S, Morrow DA, Eid SM.  Clin Cardiol. 2019 Dec 11. doi: 10.1002/clc.23317.

Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. Skranes JB, Claggett BL, Myhre PL, Lyngbakken MN, Solomon SD, Sabatine MS, Pfeffer MA, Omland T.  Circulation. 2019 Dec 10;140(24):2044-2046. doi: 10.1161/CIRCULATIONAHA.119.041991. Epub 2019 Dec 9.

Veno-Arterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock: An Introduction for the Busy Clinician. Eckman PM, Katz JN, El Banayosy A, Bohula EA, Sun B, van Diepen S.  Circulation. 2019 Dec 10;140(24):2019-2037. doi: 10.1161/CIRCULATIONAHA.119.034512. Epub 2019 Dec 9.

Baseline Characteristics of the VANISH Cohort. Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY.  Circ Heart Fail. 2019 Dec;12(12):e006231. doi: 10.1161/CIRCHEARTFAILURE.119.006231. Epub 2019 Dec 9.

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP.  Eur Heart J. 2019 Dec 7. pii: ehz821. doi: 10.1093/eurheartj/ehz821. [Epub ahead of print].

Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Inciardi RM, Giugliano RP, Claggett B, Gupta DK, Chandra A, Ruff CT, Antman EM, Mercuri MF, Grosso MA, Braunwald E, Solomon SD; ENGAGE AF-TIMI 48 Investigators. Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1606. [Epub ahead of print].

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial. Kosiborod MN, Jhund P, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køeber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJV. Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044138.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, Demets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJV. Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044133.

Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. Blood AJ, Fischer CM, Fera LE, MacLean TE, Smith KV, Dunning JR, Bosque-Hamilton JW, Aronson SJ, Gaziano TA, MacRae CA, Matta LS, Mercurio-Pinto AA, Murphy SN, Scirica BM, Wagholikar K, Desai AS. Clin Cardiol. 2019 Nov 14. doi: 10.1002/clc.23291.

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MSRuff CTCirculation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.043805.

REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States. Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044440.

Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Berg DD, Barnett CF, Kenigsberg BB, Papolos A, Alviar CL, Baird-Zars VM, Barsness GW, Bohula EA, Brennan J, Burke JA, Carnicelli AP, Chaudhry SP, Cremer PC, Daniels LB, DeFilippis AP, Gerber DA, Granger CB, Hollenberg S, Horowitz JM, Gladden JD, Katz JN, Keeley EC, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Miller PE, Nativi-Nicolau J, Newby LK, Park JG, Phreaner N, Roswell RO, Schulman SP, Sinha SS, Snell RJ, Solomon MA, Teuteberg JJ, Tymchak W, van Diepen S, Morrow DACirc Heart Fail. 2019 Nov;12(11):e006635. doi: 10.1161/CIRCHEARTFAILURE.119.006635. Epub 2019 Nov 11.

Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. Samsky M, Krucoff M, Althouse AD, Abraham WT, Adamson P, Aguel F, Bilazarian S, Dangas GD, Gilchrist IC, Henry TD, Hochman JS, Kapur NK, Laschinger J, Masters RG, Michelson E, Morrow DA, Morrow V, Ohman EM, Pina I, Proudfoot AG, Rogers J, Sapirstein J, Senatore F, Stockbridge N, Thiele H, Truesdell AG, Waksman R, Rao S. Am Heart J. 2019 Nov 7;219:1-8. doi: 10.1016/j.ahj.2019.10.006.

Reply: Anticoagulants in Atrial Fibrillation and Liver Disease. Qamar A, Antman EMGiugliano RPJ Am Coll Cardiol. 2019 Nov 12;74(19):2436-2437. doi: 10.1016/j.jacc.2019.09.010. No abstract available.

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Bhatt DL, Verma S, Braunwald E. Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008.

Efficacy and Safety of Edoxaban Compared to Warfarin According to the Burden of Diseases in Patients with Atrial Fibrillation: Insights from the ENGAGE AF-TIMI 48. Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EMGiugliano RPEur Heart J Cardiovasc Pharmacother. 2019 Nov 5. pii: pvz061. doi: 10.1093/ehjcvp/pvz061.

Diastolic Dysfunction in Patients with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results from the CHART Study. Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E.J Card Fail. 2019 Nov 1. pii: S1071-9164(19)30584-6. doi: 10.1016/j.cardfail.2019.10.011.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. McClung MR, O’Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MPWiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. Lancet Diabetes Endocrinol. 2019 Oct 29. pii: S2213-8587(19)30346-8. doi: 10.1016/S2213-8587(19)30346-8.

Response by Kato et al to Letter Regarding Article, “Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus”. Kato ET, Sabatine MSWiviott SDCirculation. 2019 Oct 29;140(18):e740-e741. doi:10.1161/CIRCULATIONAHA.119.042848.

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Koren MJ, Sabatine MSGiugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. J Am Coll Cardiol. 2019 Oct 29;74(17):2132-2146. doi: 10.1016/j.jacc.2019.08.1024.

Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial. Xu H, Bonaca MP, Goodrich E, Scirica BMMorrow DAEur Heart J Acute Cardiovasc Care. 2019 Oct 23:2048872619883354. doi: 10.1177/2048872619883354.

Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Bergmark BA, Kamphuisen PW, Wiviott SDRuff CTAntman EM, Nordio F, Kuder JF, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RPCirculation. 2019 Oct 10. doi: 10.1161/CIRCULATIONAHA.119.041346.

Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. Doehner W, Mazighi M, Hofmann BM, Lautsch D, Hindricks G, Bohula EA, Byrne RA, Camm AJ, Casadei B, Caso V, Cognard C, Diener HC, Endres M, Goldstein P, Halliday A, Hopewell JC, Jovanovic DR, Kobayashi A, Kostrubiec M, Krajina A, Landmesser U, Markus HS, Ntaios G, Pezzella FR, Ribo M, Rosano GM, Rubiera M, Sharma M, Touyz RM, Widimsky P. Eur J Prev Cardiol. 2019 Sep 30:2047487319873460. doi: 10.1177/2047487319873460.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. N Engl J Med. 2019 Sep 19. doi: 10.1056/NEJMoa1911303.

Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. Kwong RY, Heydari B, Ge Y, Abdullah S, Fujikura K, Kaneko K, Harris WS, Jerosch-Herold M, Antman EM, Seidman JG, Pfeffer MA. PLoS One. 2019 Sep 18;14(9):e0222061. doi: 10.1371/journal.pone.0222061. eCollection 2019.

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Marston NA, Giugliano RP, Im K, Silverman MG, O’Donoghue MLWiviott SD, Ference BA, Sabatine MSCirculation. 2019 Oct 15;140(16):1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998. Epub 2019 Sep 18.

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, Mc-Guire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. Eur Heart J. 2019 Aug 31. pii: ehz455. doi: 10.1093/eurheartj/ehz455.

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MSJAMA. 2019 Sep 2. doi: 10.1001/jama.2019.14120.

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Berg DD, Wiviott SDScirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MSCirculation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685.

Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for Mortality. Jentzer JC, Anavekar NS, Bennett C, Murphree DH, Keegan MT, Wiley B, Morrow DA, Murphy JG, Bell MR, Barsness GW. J Am Heart Assoc. 2019 Sep 3;8(17):e013675. doi: 10.1161/JAHA.119.013675.

In Memoriam-John Ross Jr, MD: 1928-2019. Braunwald E. JAMA Cardiol. 2019 Aug 28. doi: 10.1001/jamacardio.2019.3057.

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. Qamar A, Giugliano RPBohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DAJ Am Coll Cardiol. 2019 Aug 27;74(8):1057-1068. doi: 10.1016/j.jacc.2019.06.038.

SGLT-2 inhibitors for people with type 2 diabetes – Authors’ reply. Zelniker TA, Wiviott SD, Raz I, Sabatine MSLancet. 2019 Aug 17;394(10198):560-561. doi: 10.1016/S0140-6736(19)30699-3. No abstract available.

Quantitative EEG reactivity and machine learning for prognostication in hypoxic-ischemic brain injury. Amorim E, van der Stoel M, Nagaraj SB, Ghassemi MM, Jing J, O’Reilly UM, Scirica BM, Lee JW, Cash SS, Westover MB. Clin Neurophysiol. 2019 Oct;130(10):1908-1916. doi: 10.1016/j.clinph.2019.07.014. Epub 2019 Jul 25.

Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DACirculation. 2019 Nov 12;140(20):1661-1678. doi: 10.1161/CIRCULATIONAHA.119.040631.

Performance of acute coronary syndrome approaches in Brazil. A report from the BRACE (Brazilian Registry in Acute Coronary syndromEs). Franken M, Giugliano RP, Goodman SG, Baracioli LM, Godoy LC, Furtado RHM, Lima FG, Nicolau JC. Eur Heart J Qual Care Clin Outcomes. 2019 Aug 10. pii: qcz045. doi: 10.1093/ehjqcco/qcz045.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Circulation. 2019 Jul 2;140(2):80-91.

Diabetes, heart failure, and renal dysfunction: The vicious circles. Braunwald E. Prog Cardiovasc Dis. 2019 Jul – Aug;62(4):298-302. doi: 10.1016/j.pcad.2019.07.003. Epub 2019 Aug 1. Review.

Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Circulation. 2019 Sep 17;140(12):1004-1014. doi: 10.1161/CIRCULATIONAHA.119.040144. Epub 2019 Jul 31.

Featuring: Eugene Braunwald. Braunwald E. Eur Cardiol. 2019 Jul 11;14(2):130-133. doi: 10.15420/ecr.2019.14.2.CM1. eCollection 2019 Jul.

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CTAntman EM, Braunwald E Giugliano RPHypertension. 2019 Sep;74(3):597-605. doi: 10.1161/HYPERTENSIONAHA.119.13138.

Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units: The Critical Care Cardiology Trials Network Prospective North American Multicenter Registry of Cardiac Critical Illness. Bohula EA, Katz JN, van Diepen S, Alviar CL, Baird-Zars VM, Park JG, Barnett CF, Bhattal G, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis A, Granger CB, Hollenberg S, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Phreaner N, Roswell RO, Schulman SP, Snell RJ, Solomon MA, Ternus B, Tymchak W, Vikram F, Morrow DA; Critical Care Cardiology Trials Network. JAMA Cardiol. 2019 Jul 24. doi: 10.1001/jamacardio.2019.2467.

PCSK9 inhibitors: what we know, what we should have understood, and what is to come. Sabatine MSEur Heart J. 2019 Jul 23. pii: ehz514. doi: 10.1093/eurheartj/ehz514.

Impact of ADCY9 Genotype on Response to Anacetrapib. Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R; HPS3/TIMI55 – REVEAL Collaborative Group. Circulation. 2019 Jul 23. doi: 10.1161/CIRCULATIONAHA.119.041546.

Will Cardiac Intensive Care Unit Admissions Warrant Appropriate Use Criteria in the Future? van Diepen S, Katz JN, Morrow DACirculation. 2019 Jul 23;140(4):267-269. doi: 10.1161/CIRCULATIONAHA.118.039125.

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. JAMA Cardiol. 2019 Jul 17. doi: 10.1001/jamacardio.2019.2306.

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1548.

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Qamar A, Antman EMRuff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RPJ Am Coll Cardiol. 2019 Jul 16;74(2):179-189. doi: 10.1016/j.jacc.2019.04.061.

Microvascular Disease, Peripheral Artery Disease, and Amputation. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, Bedimo RJ, Butt AA, Marconi VC, Sico JJ, Tindle HA, Bonaca MP, Aday AW, Freiberg MS. Circulation. 2019 Aug 6;140(6):449-458. doi: 10.1161/CIRCULATIONAHA.119.040672.

Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. Jentzer JC, van Diepen S, Barsness GW, Katz JN, Wiley BM, Bennett CE, Mankad SV, Sinak LJ, Best PJ, Herrmann J, Jaffe AS, Murphy JG, Morrow DA, Wright RS, Bell MR, Anavekar NS. Am Heart J. 2019 Sep;215:12-19. doi: 10.1016/j.ahj.2019.05.012.

Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. Wagholikar KB, Ainsworth L, Vernekar VP, Pathak A, Glynn C, Zelle D, Zagade A, Karipineni N, Herrick CD, McPartlin M, Bui TV, Mendis M, Klann J, Oates M, Gordon W, Cannon C, Patel R, Aronson SJ, MacRae CA, Scirica BM, Murphy SN. AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:370-378. eCollection 2019.

Quantitative Electroencephalogram Trends Predict Recovery in Hypoxic-Ischemic Encephalopathy. Ghassemi MM, Amorim E, Alhanai T, Lee JW, Herman ST, Sivaraju A, Gaspard N, Hirsch LJ, Scirica BM, Biswal S, Moura Junior V, Cash SS, Brown EN, Mark RG, Westover MB; Critical Care Electroencephalogram Monitoring Research Consortium. Crit Care Med. 2019 Oct;47(10):1416-1423. doi: 10.1097/CCM.0000000000003840.

Utilization and outcomes of early respiratory support in 6.5 million acute heart failure hospitalizations. Metkus TS, Stephens RS, Schulman S, Hsu S, Morrow DA, Eid SM. Eur Heart J Qual Care Clin Outcomes. 2019 Jun 21. pii: qcz030. doi: 10.1093/ehjqcco/qcz030.

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MSEur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020.

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12. Review.

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10. Erratum in: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20.

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP; FOURIER Steering Committee and Investigators. J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513. Erratum in: J Am Coll Cardiol. 2019 Aug 27;74(8):1162-1166.

Correctly understanding the diabetes data in FOURIER. Sabatine MSGiugliano RP, Leiter LA. Diabetes Obes Metab. 2019 Oct;21(10):2342-2343. doi: 10.1111/dom.13812. Epub 2019 Jul 4.

Response. Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel. Chest. 2019 Jun;155(6):1311-1312. doi: 10.1016/j.chest.2019.03.037.

Response. Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel. Chest. 2019 Jun;155(6):1309. doi: 10.1016/j.chest.2019.03.001.

Response. Lip GYH, Ruff CT, Moores L; 2018 CHEST guideline Expert Panel. Chest. 2019 Jun;155(6):1307. doi: 10.1016/j.chest.2019.02.329.

Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Turcot V, Lu Y, Highland HM, Schurmann C, Justice AE, Fine RS, Bradfield JP, Esko T, Giri A, Graff M, Guo X, Hendricks AE, Karaderi T, Lempradl A, Locke AE, Mahajan A, Marouli E, Sivapalaratnam S, Young KL, Alfred T, Feitosa MF, Masca NGD, Manning AK, Medina-Gomez C, Mudgal P, Ng MCY, Reiner AP, Vedantam S, Willems SM, Winkler TW, Abecasis G, Aben KK, Alam DS, Alharthi SE, Allison M, Amouyel P, Asselbergs FW, Auer PL, Balkau B, Bang LE, Barroso I, Bastarache L, Benn M, Bergmann S, Bielak LF, Blüher M, Boehnke M, Boeing H, Boerwinkle E, Böger CA, Bork-Jensen J, Bots ML, Bottinger EP, Bowden DW, Brandslund I, Breen G, Brilliant MH, Broer L, Brumat M, Burt AA, Butterworth AS, Campbell PT, Cappellani S, Carey DJ, Catamo E, Caulfield MJ, Chambers JC, Chasman DI, Chen YI, Chowdhury R, Christensen C, Chu AY, Cocca M, Collins FS, Cook JP, Corley J, Galbany JC, Cox AJ, Crosslin DS, Cuellar-Partida G, D’Eustacchio A, Danesh J, Davies G, Bakker PIW, Groot MCH, Mutsert R, Deary IJ, Dedoussis G, Demerath EW, Heijer M, Hollander AI, Ruijter HM, Dennis JG, Denny JC, Di Angelantonio E, Drenos F, Du M, Dubé MP, Dunning AM, Easton DF, Edwards TL, Ellinghaus D, Ellinor PT, Elliott P, Evangelou E, Farmaki AE, Farooqi IS, Faul JD, Fauser S, Feng S, Ferrannini E, Ferrieres J, Florez JC, Ford I, Fornage M, Franco OH, Franke A, Franks PW, Friedrich N, Frikke-Schmidt R, Galesloot TE, Gan W, Gandin I, Gasparini P, Gibson J, Giedraitis V, Gjesing AP, Gordon-Larsen P, Gorski M, Grabe HJ, Grant SFA, Grarup N, Griffiths HL, Grove ML, Gudnason V, Gustafsson S, Haessler J, Hakonarson H, Hammerschlag AR, Hansen T, Harris KM, Harris TB, Hattersley AT, Have CT, Hayward C, He L, Heard-Costa NL, Heath AC, Heid IM, Helgeland Ø, Hernesniemi J, Hewitt AW, Holmen OL, Hovingh GK, Howson JMM, Hu Y, Huang PL, Huffman JE, Ikram MA, Ingelsson E, Jackson AU, Jansson JH, Jarvik GP, Jensen GB, Jia Y, Johansson S, Jørgensen ME, Jørgensen T, Jukema JW, Kahali B, Kahn RS, Kähönen M, Kamstrup PR, Kanoni S, Kaprio J, Karaleftheri M, Kardia SLR, Karpe F, Kathiresan S, Kee F, Kiemeney LA, Kim E, Kitajima H, Komulainen P, Kooner JS, Kooperberg C, Korhonen T, Kovacs P, Kuivaniemi H, Kutalik Z, Kuulasmaa K, Kuusisto J, Laakso M, Lakka TA, Lamparter D, Lange EM, Lange LA, Langenberg C, Larson EB, Lee NR, Lehtimäki T, Lewis CE, Li H, Li J, Li-Gao R, Lin H, Lin KH, Lin LA, Lin X, Lind L, Lindström J, Linneberg A, Liu CT, Liu DJ, Liu Y, Lo KS, Lophatananon A, Lotery AJ, Loukola A, Luan J, Lubitz SA, Lyytikäinen LP, Männistö S, Marenne G, Mazul AL, McCarthy MI, McKean-Cowdin R, Medland SE, Meidtner K, Milani L, Mistry V, Mitchell P, Mohlke KL, Moilanen L, Moitry M, Montgomery GW, Mook-Kanamori DO, Moore C, Mori TA, Morris AD, Morris AP, Müller-Nurasyid M, Munroe PB, Nalls MA, Narisu N, Nelson CP, Neville M, Nielsen SF, Nikus K, Njølstad PR, Nordestgaard BG, Nyholt DR, O’Connel JR, O’Donoghue ML, Loohuis LMO, Ophoff RA, Owen KR, Packard CJ, Padmanabhan S, Palmer CNA, Palmer ND, Pasterkamp G, Patel AP, Pattie A, Pedersen O, Peissig PL, Peloso GM, Pennell CE, Perola M, Perry JA, Perry JRB, Pers TH, Person TN, Peters A, Petersen ERB, Peyser PA, Pirie A, Polasek O, Polderman TJ, Puolijoki H, Raitakari OT, Rasheed A, Rauramaa R, Reilly DF, Renström F, Rheinberger M, Ridker PM, Rioux JD, Rivas MA, Roberts DJ, Robertson NR, Robino A, Rolandsson O, Rudan I, Ruth KS, Saleheen D, Salomaa V, Samani NJ, Sapkota Y, Sattar N, Schoen RE, Schreiner PJ, Schulze MB, Scott RA, Segura-Lepe MP, Shah SH, Sheu WH, Sim X, Slater AJ, Small KS, Smith AV, Southam L, Spector TD, Speliotes EK, Starr JM, Stefansson K, Steinthorsdottir V, Stirrups KE, Strauch K, Stringham HM, Stumvoll M, Sun L, Surendran P, Swift AJ, Tada H, Tansey KE, Tardif JC, Taylor KD, Teumer A, Thompson DJ, Thorleifsson G, Thorsteinsdottir U, Thuesen BH, Tönjes A, Tromp G, Trompet S, Tsafantakis E, Tuomilehto J, Tybjaerg-Hansen A, Tyrer JP, Uher R, Uitterlinden AG, Uusitupa M, Laan SW, Duijn CM, Leeuwen N, van Setten J, Vanhala M, Varbo A, Varga TV, Varma R, Edwards DRV, Vermeulen SH, Veronesi G, Vestergaard H, Vitart V, Vogt TF, Völker U, Vuckovic D, Wagenknecht LE, Walker M, Wallentin L, Wang F, Wang CA, Wang S, Wang Y, Ware EB, Wareham NJ, Warren HR, Waterworth DM, Wessel J, White HD, Willer CJ, Wilson JG, Witte DR, Wood AR, Wu Y, Yaghootkar H, Yao J, Yao P, Yerges-Armstrong LM, Young R, Zeggini E, Zhan X, Zhang W, Zhao JH, Zhao W, Zhao W, Zhou W, Zondervan KT; CHD Exome+ Consortium; EPIC-CVD Consortium; ExomeBP Consortium; Global Lipids Genetic Consortium; GoT2D Genes Consortium; EPIC InterAct Consortium; INTERVAL Study; ReproGen Consortium; T2D-Genes Consortium; MAGIC Investigators; Understanding Society Scientific Group, Rotter JI, Pospisilik JA, Rivadeneira F, Borecki IB, Deloukas P, Frayling TM, Lettre G, North KE, Lindgren CM, Hirschhorn JN, Loos RJF. Nat Genet. 2019 Jul;51(7):1191-1192. doi: 10.1038/s41588-019-0447-2.

A catalog of genetic loci associated with kidney function from analyses of a million individuals. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, Tin A, Wang L, Chu AY, Hoppmann A, Kirsten H, Giri A, Chai JF, Sveinbjornsson G, Tayo BO, Nutile T, Fuchsberger C, Marten J, Cocca M, Ghasemi S, Xu Y, Horn K, Noce D, van der Most PJ, Sedaghat S, Yu Z, Akiyama M, Afaq S, Ahluwalia TS, Almgren P, Amin N, Ärnlöv J, Bakker SJL, Bansal N, Baptista D, Bergmann S, Biggs ML, Biino G, Boehnke M, Boerwinkle E, Boissel M, Bottinger EP, Boutin TS, Brenner H, Brumat M, Burkhardt R, Butterworth AS, Campana E, Campbell A, Campbell H, Canouil M, Carroll RJ, Catamo E, Chambers JC, Chee ML, Chee ML, Chen X, Cheng CY, Cheng Y, Christensen K, Cifkova R, Ciullo M, Concas MP, Cook JP, Coresh J, Corre T, Sala CF, Cusi D, Danesh J, Daw EW, de Borst MH, De Grandi A, de Mutsert R, de Vries APJ, Degenhardt F, Delgado G, Demirkan A, Di Angelantonio E, Dittrich K, Divers J, Dorajoo R, Eckardt KU, Ehret G, Elliott P, Endlich K, Evans MK, Felix JF, Foo VHX, Franco OH, Franke A, Freedman BI, Freitag-Wolf S, Friedlander Y, Froguel P, Gansevoort RT, Gao H, Gasparini P, Gaziano JM, Giedraitis V, Gieger C, Girotto G, Giulianini F, Gögele M, Gordon SD, Gudbjartsson DF, Gudnason V, Haller T, Hamet P, Harris TB, Hartman CA, Hayward C, Hellwege JN, Heng CK, Hicks AA, Hofer E, Huang W, Hutri-Kähönen N, Hwang SJ, Ikram MA, Indridason OS, Ingelsson E, Ising M, Jaddoe VWV, Jakobsdottir J, Jonas JB, Joshi PK, Josyula NS, Jung B, Kähönen M, Kamatani Y, Kammerer CM, Kanai M, Kastarinen M, Kerr SM, Khor CC, Kiess W, Kleber ME, Koenig W, Kooner JS, Körner A, Kovacs P, Kraja AT, Krajcoviechova A, Kramer H, Krämer BK, Kronenberg F, Kubo M, Kühnel B, Kuokkanen M, Kuusisto J, La Bianca M, Laakso M, Lange LA, Langefeld CD, Lee JJ, Lehne B, Lehtimäki T, Lieb W; Lifelines Cohort Study, Lim SC, Lind L, Lindgren CM, Liu J, Liu J, Loeffler M, Loos RJF, Lucae S, Lukas MA, Lyytikäinen LP, Mägi R, Magnusson PKE, Mahajan A, Martin NG, Martins J, März W, Mascalzoni D, Matsuda K, Meisinger C, Meitinger T, Melander O, Metspalu A, Mikaelsdottir EK, Milaneschi Y, Miliku K, Mishra PP; V. A. Million Veteran Program, Mohlke KL, Mononen N, Montgomery GW, Mook-Kanamori DO, Mychaleckyj JC, Nadkarni GN, Nalls MA, Nauck M, Nikus K, Ning B, Nolte IM, Noordam R, O’Connell J, O’Donoghue ML, Olafsson I, Oldehinkel AJ, Orho-Melander M, Ouwehand WH, Padmanabhan S, Palmer ND, Palsson R, Penninx BWJH, Perls T, Perola M, Pirastu M, Pirastu N, Pistis G, Podgornaia AI, Polasek O, Ponte B, Porteous DJ, Poulain T, Pramstaller PP, Preuss MH, Prins BP, Province MA, Rabelink TJ, Raffield LM, Raitakari OT, Reilly DF, Rettig R, Rheinberger M, Rice KM, Ridker PM, Rivadeneira F, Rizzi F, Roberts DJ, Robino A, Rossing P, Rudan I, Rueedi R, Ruggiero D, Ryan KA, Saba Y, Sabanayagam C, Salomaa V, Salvi E, Saum KU, Schmidt H, Schmidt R, Schöttker B, Schulz CA, Schupf N, Shaffer CM, Shi Y, Smith AV, Smith BH, Soranzo N, Spracklen CN, Strauch K, Stringham HM, Stumvoll M, Svensson PO, Szymczak S, Tai ES, Tajuddin SM, Tan NYQ, Taylor KD, Teren A, Tham YC, Thiery J, Thio CHL, Thomsen H, Thorleifsson G, Toniolo D, Tönjes A, Tremblay J, Tzoulaki I, Uitterlinden AG, Vaccargiu S, van Dam RM, van der Harst P, van Duijn CM, Velez Edward DR, Verweij N, Vogelezang S, Völker U, Vollenweider P, Waeber G, Waldenberger M, Wallentin L, Wang YX, Wang C, Waterworth DM, Bin Wei W, White H, Whitfield JB, Wild SH, Wilson JF, Wojczynski MK, Wong C, Wong TY, Xu L, Yang Q, Yasuda M, Yerges-Armstrong LM, Zhang W, Zonderman AB, Rotter JI, Bochud M, Psaty BM, Vitart V, Wilson JG, Dehghan A, Parsa A, Chasman DI, Ho K, Morris AP, Devuyst O, Akilesh S, Pendergrass SA, Sim X, Böger CA, Okada Y, Edwards TL, Snieder H, Stefansson K, Hung AM, Heid IM, Scholz M, Teumer A, Köttgen A, Pattaro C. Nat Genet. 2019 Jun;51(6):957-972. doi: 10.1038/s41588-019-0407-x. Epub 2019 May 31.

Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. Wagholikar KB, Fischer CM, Goodson AP, Herrick CD, Maclean TE, Smith KV, Fera L, Gaziano TA, Dunning JR, Bosque-Hamilton J, Matta L, Toscano E, Richter B, Ainsworth L, Oates MF, Aronson S, MacRae CA, Scirica BM, Desai AS, Murphy SN. J Clin Med Res. 2019 Jun;11(6):458-463. doi: 10.14740/jocmr3830. Epub 2019 May 10.

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MSJAMA Cardiol. 2019 Jul 1;4(7):613-619. doi: 10.1001/jamacardio.2019.0886.

Andexanet Alfa (Andexxa) Formulary Review. Beik N, Reddy P, Sylvester KW, Connell NT, Giugliano RP, Piazza G, Connors JM. Crit Pathw Cardiol. 2019 Jun;18(2):66-71. doi: 10.1097/HPC.0000000000000177.

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Eur Heart J. 2019 Oct 21;40(40):3345-3352. doi: 10.1093/eurheartj/ehz240.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. Wiviott SD, Raz I, Sabatine MS.N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837.

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG. JAMA. 2019 May 7;321(17):1693-1701. doi: 10.1001/jama.2019.4973.

Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. Qamar A, Giugliano RPSabatine MSJAMA Cardiol. 2019 Jun 1;4(6):600-601. doi: 10.1001/jamacardio.2019.1200.

Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MSMorrow DAJ Am Heart Assoc. 2019 May 7;8(9):e011444. doi: 10.1161/JAHA.118.011444.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BMClin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

Incremental costs of high intensive care utilisation in patients hospitalised with heart failure. van Diepen S, Tran DT, Ezekowitz JA, Schnell G, Wiley BM, Morrow DA, McAlister FA, Kaul P. Eur Heart J Acute Cardiovasc Care. 2019 Oct;8(7):660-666. doi: 10.1177/2048872619845282. Epub 2019 Apr 12.

The Changing Face of Cardiogenic Shock: A Challenge in Cardiac Critical Care. Morrow DAJ Am Coll Cardiol. 2019 Apr 16;73(14):1792-1794. doi: 10.1016/j.jacc.2019.02.022.

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.

RESPONSE: Transition to Early Career in Critical Care Cardiology: Know Who You Want to Be. Morrow DAJ Am Coll Cardiol. 2019 Apr 9;73(13):1730. doi: 10.1016/j.jacc.2019.03.005.

Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL. J Am Coll Cardiol. 2019 Apr 2;73(12):1596-1598. doi: 10.1016/j.jacc.2019.01.029.

Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RPJ Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349. doi: 10.1016/j.jacc.2019.01.017.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators.Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MSWiviott SDCirculation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MPRuff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MSWiviott SDCirculation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

Role of Critical Care Medicine Training in the Cardiovascular Intensive Care Unit: Survey Responses From Dual Certified Critical Care Cardiologists. Brusca SB, Barnett C, Barnhart BJ, Weng W, Morrow DA, Soble JS, Katz JN, Wiley BM, van Diepen S, Gomez AD, Solomon MA. J Am Heart Assoc. 2019 Mar 19;8(6):e011721. doi: 10.1161/JAHA.118.011721.

Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis AP, Haleem A, Hollenberg SM, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Park JG, Phreaner N, Roswell RO, Schulman SP, Jeffrey Snell R, Solomon MA, Ternus B, Tymchak W, Vikram F, Morrow DACirc Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.

Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Furtado RHM, Giugliano RP, Dalcoquio TF, Arantes FBB, Barbosa CJDG, Genestreti PRR, Franci A, Menezes FR, Nakashima CAK, Scanavini Filho MA, Ferrari AG, Salsoso R, Baracioli LM, Nicolau JC. J Thromb Thrombolysis. 2019 Aug;48(2):217-224. doi: 10.1007/s11239-019-01830-z.

The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade? Bonow RO, Braunwald E. JAMA. 2019 Mar 19;321(11):1053-1054. doi: 10.1001/jama.2019.2018.

DOACs in Patients With Mitral Stenosis and Atrial Fibrillation: Time for a Randomized Clinical Trial. Giugliano RP, O’Gara PT. J Am Coll Cardiol. 2019 Mar 19;73(10):1132-1134. doi: 10.1016/j.jacc.2018.12.048.

Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial. Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BMBonaca MPVasc Med. 2019 Apr;24(2):159-161. doi: 10.1177/1358863X19826681. Epub 2019 Mar 14.

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. Zelniker TA, Braunwald E. Card Fail Rev. 2019 Feb;5(1):27-30. doi: 10.15420/cfr.2018.44.1.

Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. Januzzi JL Jr, Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, Morrow DA, Jaffe AS. J Am Coll Cardiol. 2019 Mar 12;73(9):1059-1077. doi: 10.1016/j.jacc.2018.12.046. Epub 2019 Feb 21.

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MSCirculation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

Klotho, fibroblast growth factor-23, and the renin-angiotensin system – an analysis from the PEACE trial. Bergmark BA, Udell JA, Morrow DA, Jarolim P, Kuder JF, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MSEur J Heart Fail. 2019 Apr;21(4):462-470. doi: 10.1002/ejhf.1424. Epub 2019 Feb 18.

Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Kessler T, Wolf B, Eriksson N, Kofink D, Mahmoodi BK, Rai H, Tragante V, Åkerblom A, Becker RC, Bernlochner I, Bopp R, James S, Katus HA, Mayer K, Munz M, Nordio F, O’Donoghue ML, Sager HB, Sibbing D, Solakov L, Storey RF, Wobst J, Asselbergs FW, Byrne RA, Erdmann J, Koenig W, Laugwitz KL, Ten Berg JM, Wallentin L, Kastrati A, Schunkert H. Cardiovasc Res. 2019 Aug 1;115(10):1512-1518. doi: 10.1093/cvr/cvz015.

Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. Baugh CW, Scirica BM, Januzzi JL, Morrow DA, Lewandrowski KB, Jarolim P, White BA, Weinfeld MS, Hoffmann U, Nagurney JT. Crit Pathw Cardiol. 2019 Mar;18(1):1-4. doi: 10.1097/HPC.0000000000000164. No abstract available.

Classification of Deaths in Cardiovascular Outcomes Trials. Morrow DAWiviott SDCirculation. 2019 Feb 12;139(7):874-876. doi: 10.1161/CIRCULATIONAHA.118.038359.

Stroke prevention in atrial fibrillation: Closing the gap. Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM, Kline-Rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB. Am Heart J. 2019 Apr;210:29-38. doi: 10.1016/j.ahj.2018.10.004. Epub 2018 Oct 25.

Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park JG, Bonaca MPScirica BMMorrow DAClin Chem Lab Med. 2019 Jun 26;57(7):1084-1092. doi: 10.1515/cclm-2018-1081.

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. JAMA. 2019 Jan 29;321(4):364-373. doi: 10.1001/jama.2018.20045.

Cardiology and Therapy: A Summary of 2018 and Key Areas of Emerging Research in 2019. Menown IBA, Giugliano RP, Zeymer U. Cardiol Ther. 2019 Jun;8(1):1-3. doi: 10.1007/s40119-019-0125-6. Epub 2019 Jan 25.

Medication Discontinuation in the IMPROVE-IT Trial. Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA. Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041.

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RPEur Heart J. 2019 May 14;40(19):1541-1550. doi: 10.1093/eurheartj/ehy861.

Lorcaserin Safety in Overweight or Obese Patients. Bohula EAWiviott SDScirica BMN Engl J Med. 2019 Jan 3;380(1):100. doi: 10.1056/NEJMc1813971.

Improving Care of STEMI in the United States 2008 to 2012. Granger CB, Bates ER, Jollis JG, Antman EM, Nichol G, O’Connor RE, Gregory T, Roettig ML, Peng SA, Ellrodt G, Henry TD, French WJ, Jacobs AK. J Am Heart Assoc. 2019 Jan 8;8(1):e008096. doi: 10.1161/JAHA.118.008096.

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RPEur Heart J. 2019 May 14;40(19):1492-1500. doi: 10.1093/eurheartj/ehy802.

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RPEur Heart J. 2019 May 14;40(19):1518-1527. doi: 10.1093/eurheartj/ehy807.

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close